NewsBenzingaBioventus: l’EPS rettificato del terzo trimestre a $0,17 supera la stima di $0,16, le vendite a $142,442 milioni mancano la stima di $149,461 milioni Bioventus: l’EPS rettificato del terzo trimestre a $0,17 supera la stima di $0,16, le vendite a $142,442 milioni mancano la stima di $149,461 milioni Benzinga 2026.11.02 21:09 (GMT+0) Open on Benzinga Other news Swoosh and a Miss: Nike Investor Day Leaves Wall Street Cold-Footed Wall Street Says the AI Trade Is Over — ETF Investors Aren’t Acting Like It Citigroup Maintains Neutral on Westlake, Lowers Price Target to $65 Citigroup Maintains Neutral on LyondellBasell Industries, Lowers Price Target to $66 Caterpillar's 'Best-In-Class' Construction Business Is Getting Overlooked, Analyst Says How to Play NKE Stock as Nike Risks Becoming a Forever Turnaround Story